Page 607 - Williams Hematology ( PDFDrive )

582 Part VI: The Erythrocyte

26. Inoue N, Izui-Sarumaru T, Murakami Y, et al: Molecular basis of clonal expansion of 56. Ferreira VP, Pangburn MK: Factor H mediated cell surface protection from comple-
hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood ment is critical for the survival of PNH erythrocytes. Blood 110:2190, 2007.
108:4232, 2006. 57. Rosse WF: Treatment of paroxysmal nocturnal hemoglobinuria. Blood 60:20, 1982.
27. Endo M, Ware RE, Vreeke TM, et al: Molecular basis of the heterogeneity of expression 58. Hartmann RC, Jenkins DE Jr, McKee LC, Heyssel RM: Paroxysmal nocturnal hemoglo-
of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglo- binuria: Clinical and laboratory studies relating to iron metabolism and therapy with
binuria. Blood 87:2546, 1996. androgen and iron. Medicine (Baltimore) 45:331, 1966.
28. Parker C, Omine M, Richards S, et al: Diagnosis and management of paroxysmal noc- 59. Brecher ME, Taswell HF: Paroxysmal nocturnal hemoglobinuria and the transfusion of
turnal hemoglobinuria. Blood 106:3699, 2005. washed red cells: A myth revisited. Transfusion 29:681, 1989.
29. Dacie JV, Lewis SM: Paroxysmal nocturnal haemoglobinuria: Clinical manifestations, 60. Kelly RJ, Hill A, Arnold LM, et al: Long-term treatment with eculizumab in paroxysmal
haematology, and nature of the disease. Ser Haematol 5:3, 1972. nocturnal hemoglobinuria: Sustained efficacy and improved survival. Blood 117:6786,
30. Ishiyama K, Chuhjo T, Wang H, et al: Polyclonal hematopoiesis maintained in patients 2011.
with bone marrow failure harboring a minor population of paroxysmal nocturnal 61. Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al: Allogeneic stem cell trans-
hemoglobinuria-type cells. Blood 102:1211, 2003. plantation in paroxysmal nocturnal hemoglobinuria. Haematologica 97:1666, 2012.
31. Sugimori C, Chuhjo T, Feng X, et al: Minor population of CD55-CD59- blood cells pre- 62. Endo M, Beatty PG, Vreeke TM, et al: Syngeneic bone marrow transplantation without
dicts response to immunosuppressive therapy and prognosis in patients with aplastic conditioning in a patient with paroxysmal nocturnal hemoglobinuria: In vivo evidence
anemia. Blood 107:1308, 2006. that the mutant stem cells have a survival advantage. Blood 88:742, 1996.
32. Timeus F, Crescenzio N, Longoni D, et al: Paroxysmal nocturnal hemoglobinuria clones 63. Bemba M, Guardiola P, Garderet L, et al: Bone marrow transplantation for paroxysmal
in children with acquired aplastic anemia: A multicentre study. PLoS One 9:e101948, nocturnal haemoglobinuria. Br J Haematol 105:366, 1999.
2014. 64. Hegenbart U, Niederwieser D, Forman S, et al: Hematopoietic cell transplantation from
33. Wang H, Chuhjo T, Yasue S, et al: Clinical significance of a minor population of par- related and unrelated donors after minimal conditioning as a curative treatment modal-
oxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood ity for severe paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant
100:3897, 2002. 9:689, 2003.
34. Borowitz MJ, Craig FE, Digiuseppe JA, et al: Guidelines for the diagnosis and monitor- 65. Raiola AM, Van Lint MT, Lamparelli T, et al: Bone marrow transplantation for paroxys-
ing of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. mal nocturnal hemoglobinuria. Haematologica 85:59, 2000.
Cytometry B Clin Cytom 78:211, 2010. 66. Saso R, Marsh J, Cevreska L, et al: Bone marrow transplants for paroxysmal nocturnal
35. Richards SJ, Rawstron AC, Hillmen P: Application of flow cytometry to the diagnosis of haemoglobinuria. Br J Haematol 104:392, 1999.
paroxysmal nocturnal hemoglobinuria. Cytometry 42:223, 2000. 67. Takahashi Y, McCoy JP Jr, Carvallo C, et al: In vitro and in vivo evidence of PNH cell
36. Chen G, Kirby M, Zeng W, et al: Superior growth of glycophosphatidy linositol-an- sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell
chored protein-deficient progenitor cells in vitro is due to the higher apoptotic rate of transplantation. Blood 103:1383, 2004.
progenitors with normal phenotype in vivo. Exp Hematol 30:774, 2002. 68. Woodard P, Wang W, Pitts N, et al: Successful unrelated donor bone marrow trans-
37. Dunn DE, Liu JM, Young NS: Bone marrow failure in PNH, in PNH and the GPI-Linked plantation for paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplant 27:589,
Proteins, edited by NS Young, J Moss p 113. Academic Press, San Diego, 2000. 2001.
38. Sugimori C, Mochizuki K, Qi Z, et al: Origin and fate of blood cells deficient in glyco- 69. Hill A, Kelly RJ, Hillmen P: Thrombosis in paroxysmal nocturnal hemoglobinuria.
sylphosphatidylinositol-anchored protein among patients with bone marrow failure. Br Blood 121:4985, 2013.
J Haematol 147:102, 2009. 70. Hall C, Richards S, Hillmen P: Primary prophylaxis with warfarin prevents thrombosis
39. Wang SA, Pozdnyakova O, Jorgensen JL, et al: Detection of paroxysmal nocturnal in paroxysmal nocturnal hemoglobinuria (PNH). Blood 102:3587, 2003.
hemoglobinuria clones in patients with myelodysplastic syndromes and related bone 71. Moyo VM, Mukina GL, Barrett ES, Brodsky RA: Natural history of paroxysmal noctur-
marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica nal haemoglobinuria using modern diagnostic assays. Br J Haematol 126:133, 2004.
94:29, 2009. 72. Nishimura JI, Kanakura Y, Ware RE, et al: Clinical course and flow cytometric analysis
40. Curran KJ, Kernan NA, Prockop SE, et al: Paroxysmal nocturnal hemoglobinuria in of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Bal-
pediatric patients. Pediatr Blood Cancer 59:525, 2012. timore) 83:193, 2004.
41. Scheinberg P, Marte M, Nunez O, Young NS: Paroxysmal nocturnal hemoglobinuria 73. Sloand EM, Young NS: Thrombotic complications in PNH, in PNH and the GPI-Linked
clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin Proteins, edited by NS Young, J Moss, p 101. Academic Press, San Diego, 2000.
plus cyclosporine. Haematologica 95:1075, 2010. 74. Griffith JF, Mahmoud AE, Cooper S, et al: Radiological intervention in Budd-Chiari
42. de Latour RP, Mary JY, Salanoubat C, et al: Paroxysmal nocturnal hemoglobinuria: Nat- syndrome: Techniques and outcome in 18 patients. Clin Radiol 51:775, 1996.
ural history of disease subcategories. Blood 112:3099, 2008. 75. McMullin MF, Hillmen P, Jackson J, et al: Tissue plasminogen activator for hepatic vein
43. Hillmen P, Lewis SM, Bessler M, et al: Natural history of paroxysmal nocturnal hemo- thrombosis in paroxysmal nocturnal haemoglobinuria. J Intern Med 235:85, 1994.
globinuria. N Engl J Med 333:1253, 1995. 76. Sholar PW, Bell WR: Thrombolytic therapy for inferior vena cava thrombosis in parox-
44. Kulagin A, Lisukov I, Ivanova M, et al: Prognostic value of paroxysmal nocturnal hae- ysmal nocturnal hemoglobinuria. Ann Intern Med 103:539, 1985.
moglobinuria clone presence in aplastic anaemia patients treated with combined immu- 77. Ray JG, Burows RF, Ginsberg JS, Burrows EA: Paroxysmal nocturnal hemoglobinuria
nosuppression: Results of two-centre prospective study. Br J Haematol 164:546, 2014. and the risk of venous thrombosis: Review and recommendations for management of
45. Dunn DE, Tanawattanacharoen P, Boccuni P, et al: Paroxysmal nocturnal hemoglobi- the pregnant and nonpregnant patient. Haemostasis 30:103, 2000.
nuria cells in patients with bone marrow failure syndromes. Ann Intern Med 131:401, 78. Tichelli A, Socie G, Marsh J, et al: Outcome of pregnancy and disease course among
1999. women with aplastic anemia treated with immunosuppression. Ann Intern Med
46. Harris JW, Koscick R, Lazarus HM, et al: Leukemia arising out of paroxysmal nocturnal 137:164, 2002.
hemoglobinuria. Leuk Lymphoma 32:401, 1999. 79. Danilov AV, Brodsky RA, Craigo S, et al: Managing a pregnant patient with paroxysmal
47. Saunthararajah Y, Nakamura R, Nam JM, et al: HLA-DR15 (DR2) is overrepresented in nocturnal hemoglobinuria in the era of eculizumab. Leuk Res 34:566, 2010.
myelodysplastic syndrome and aplastic anemia and predicts a response to immunosup- 80. Kelly R, Arnold L, Richards S, et al: The management of pregnancy in paroxysmal noc-
pression in myelodysplastic syndrome. Blood 100:1570, 2002. turnal haemoglobinuria on long term eculizumab. Br J Haematol 149:446, 2010.
48. Sugimori C, Yamazaki H, Feng X, et al: Roles of DRB1 1501 and DRB1 1502 in the 81. Ware RE, Hall SE, Rosse WF: Paroxysmal nocturnal hemoglobinuria with onset in
*
*
pathogenesis of aplastic anemia. Exp Hematol 35:13, 2007. childhood and adolescence. N Engl J Med 325:991, 1991.
49. Parker C: Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 373:759, 82. van den Heuvel-Eibrink MM, Bredius RG, te Winkel ML, et al: Childhood paroxysmal
2009. nocturnal haemoglobinuria (PNH), a report of 11 cases in the Netherlands. Br J Haematol
50. Hillmen P, Young NS, Schubert J, et al: The complement inhibitor eculizumab in parox- 128:571, 2005.
ysmal nocturnal hemoglobinuria. N Engl J Med 355:1233, 2006. 83. Bauters T, Bordon V, Robays H, et al: Successful use of eculizumab in a pediatric patient
51. Marasca R, Coluccio V, Santachiara R, et al: Pregnancy in PNH: Another eculizumab treated for paroxysmal nocturnal hemoglobinuria. J Pediatr Hematol Oncol 34:e346,
baby. Br J Haematol 150:707, 2010. 2012.
52. Parker CJ: Thanks for the complement (inhibitor). Blood 118:4503, 2011. 84. Reiss UM, Schwartz J, Sakamoto KM, et al: Efficacy and safety of eculizumab in chil-
53. Risitano AM, Marando L, Seneca E, Rotoli B: Hemoglobin normalization after splenec- dren and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Can-
tomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood cer 2014.
112:449, 2008. 85. Socie G, Mary JY, de Gramont A, et al: Paroxysmal nocturnal haemoglobinuria: Long-
54. Hillmen P, Muus P, Duhrsen U, et al: Effect of the complement inhibitor eculizumab term follow-up and prognostic factors. French Society of Haematology. Lancet 348:573,
on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 1996.
110:4123, 2007. 86. Hillmen P, Muus P, Roth A, et al: Long-term safety and efficacy of sustained eculizumab
55. Hillmen P, Hall C, Marsh JC, et al: Effect of eculizumab on hemolysis and transfusion treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol
requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 162:62, 2013.
350:552, 2004.

Kaushansky_chapter 40_p0571-0582.indd 582 9/17/15 6:23 PM